Loading...

Athersys

DB:4LS
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4LS
DB
$210M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
4LS Share Price and Events
7 Day Returns
7.1%
DB:4LS
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-22.4%
DB:4LS
-10.6%
DE Biotechs
-6.2%
DE Market
4LS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Athersys (4LS) 7.1% -9.6% 6.4% -22.4% -35.9% 23.2%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • 4LS underperformed the Biotechs industry which returned -10.6% over the past year.
  • 4LS underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
4LS
Industry
5yr Volatility vs Market

4LS Value

 Is Athersys undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Athersys. This is due to cash flow or dividend data being unavailable. The share price is €1.3196.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Athersys's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Athersys's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4LS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.18
NasdaqCM:ATHX Share Price ** NasdaqCM (2019-04-23) in USD $1.66
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Athersys.

DB:4LS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ATHX Share Price ÷ EPS (both in USD)

= 1.66 ÷ -0.18

-9.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Athersys is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Athersys is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Athersys's expected growth come at a high price?
Raw Data
DB:4LS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
36%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Athersys, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Athersys's assets?
Raw Data
DB:4LS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.30
NasdaqCM:ATHX Share Price * NasdaqCM (2019-04-23) in USD $1.66
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:4LS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ATHX Share Price ÷ Book Value per Share (both in USD)

= 1.66 ÷ 0.30

5.56x

* Primary Listing of Athersys.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Athersys is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Athersys's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Athersys has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4LS Future Performance

 How is Athersys expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Athersys expected to grow at an attractive rate?
  • Athersys's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Athersys's earnings growth is expected to exceed the Germany market average.
  • Athersys's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:4LS Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:4LS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 36%
DB:4LS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 52.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4LS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4LS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 297 207 1
2022-12-31 12 -49 1
2021-12-31 13 -45 1
2020-12-31 7 -49 2
2019-12-31 5 -52 3
DB:4LS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 24 -13 -24
2018-09-30 24 -15 -26
2018-06-30 22 -14 -24
2018-03-31 3 -24 -37
2017-12-31 4 -24 -32
2017-09-30 4 -24 -26
2017-06-30 3 -23 -25
2017-03-31 3 -24 -26
2016-12-31 17 -11 -15
2016-09-30 27 -10 -5
2016-06-30 27 -8 -5
2016-03-31 27 -8 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Athersys's earnings are expected to grow significantly at over 20% yearly.
  • Athersys's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4LS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Athersys Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4LS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.26 1.26 1.26 1.00
2022-12-31 -0.31 -0.31 -0.31 1.00
2021-12-31 -0.29 -0.29 -0.29 1.00
2020-12-31 -0.34 -0.28 -0.39 2.00
2019-12-31 -0.35 -0.29 -0.39 3.00
DB:4LS Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.18
2018-09-30 -0.20
2018-06-30 -0.19
2018-03-31 -0.31
2017-12-31 -0.29
2017-09-30 -0.25
2017-06-30 -0.26
2017-03-31 -0.29
2016-12-31 -0.18
2016-09-30 -0.05
2016-06-30 -0.06
2016-03-31 0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Athersys will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Athersys's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Athersys has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4LS Past Performance

  How has Athersys performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Athersys's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Athersys does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Athersys's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Athersys's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Athersys's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Athersys Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4LS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 24.29 -24.28 10.44
2018-09-30 23.95 -26.06 9.67
2018-06-30 22.03 -23.57 9.23
2018-03-31 3.30 -36.77 9.05
2017-12-31 3.71 -32.24 8.47
2017-09-30 3.52 -26.27 8.40
2017-06-30 3.43 -25.03 8.11
2017-03-31 3.36 -25.72 7.89
2016-12-31 17.35 -15.34 7.84
2016-09-30 26.97 -4.62 7.62
2016-06-30 27.05 -5.11 7.73
2016-03-31 26.68 0.81 7.66
2015-12-31 11.95 -16.42 7.54
2015-09-30 1.58 -26.57 7.36
2015-06-30 1.48 -24.79 7.11
2015-03-31 1.65 -23.08 7.01
2014-12-31 1.62 -22.08 6.91
2014-09-30 2.31 -25.32 6.86
2014-06-30 2.64 -26.22 6.61
2014-03-31 2.82 -32.84 6.34
2013-12-31 2.44 -30.74 6.07
2013-09-30 3.81 -24.19 5.99 4.43
2013-06-30 4.20 -22.02 5.87 7.81
2013-03-31 6.29 -19.79 5.71 12.27
2012-12-31 8.71 -14.74 4.75
2012-09-30 8.98 -15.75 5.65 18.22
2012-06-30 10.32 -14.64 5.68 18.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Athersys has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Athersys has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Athersys improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Athersys's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Athersys has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4LS Health

 How is Athersys's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Athersys's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Athersys is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Athersys's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Athersys's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Athersys has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Athersys Company Filings, last reported 3 months ago.

DB:4LS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 43.12 0.00 51.06
2018-09-30 50.34 0.00 47.97
2018-06-30 56.25 0.00 53.35
2018-03-31 47.53 0.00 49.67
2017-12-31 23.38 0.00 29.32
2017-09-30 26.07 0.00 28.23
2017-06-30 26.02 0.00 28.59
2017-03-31 29.22 0.00 31.94
2016-12-31 11.18 0.00 14.75
2016-09-30 16.02 0.00 19.38
2016-06-30 19.77 0.00 24.02
2016-03-31 25.43 0.00 30.41
2015-12-31 19.72 0.19 23.03
2015-09-30 15.50 0.19 28.53
2015-06-30 21.38 0.19 32.35
2015-03-31 19.02 0.19 35.51
2014-12-31 20.90 0.18 26.13
2014-09-30 26.82 0.18 32.37
2014-06-30 30.88 0.18 38.75
2014-03-31 29.66 0.18 44.98
2013-12-31 19.82 0.18 31.95
2013-09-30 11.49 0.17 17.81
2013-06-30 11.77 0.17 18.90
2013-03-31 13.00 0.17 21.35
2012-12-31 20.25 0.17 25.53
2012-09-30 1.95 0.05 7.90
2012-06-30 4.50 0.05 10.86
  • Athersys has no debt.
  • Athersys has no debt compared to 5 years ago when it was 0.9%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Athersys has sufficient cash runway for more than 3 years based on current free cash flow.
  • Athersys has sufficient cash runway for 2.9 years if free cash flow continues to grow at historical rates of 17.4% each year.
X
Financial health checks
We assess Athersys's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Athersys has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4LS Dividends

 What is Athersys's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Athersys dividends.
If you bought €2,000 of Athersys shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Athersys's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Athersys's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4LS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:4LS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Athersys has not reported any payouts.
  • Unable to verify if Athersys's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Athersys's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Athersys has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Athersys's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Athersys afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Athersys has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4LS Management

 What is the CEO of Athersys's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gil Van Bokkelen
COMPENSATION $1,458,435
AGE 57
TENURE AS CEO 23.5 years
CEO Bio

Dr. Gil Van Bokkelen, Ph.D. serves as an Investment Advisor to Early Stage Partners, a venture capital fund based in Ohio. Dr. Van Bokkelen co-founded Athersys, Inc. in October 1995 and has been its Chief Executive Officer since 1995. He served as the President at Athersys, Inc. until May 2006. Dr. Van Bokkelen also played a fundamental role in developing the SMC technology. He has been the Chairman at Athersys, Inc. since August 2000 and has been its Director since 1995. He has been a Director and a Member of Health Section Governing Board at Biotechnology Industry Organization since July 2011. He has been Director of Alliance for Regenerative Medicine since 2018. He serves on the board of the Alliance for Regenerative Medicine and served as chairman from 2010 through 2012, a Washington D.C. based consortium of companies, patient advocacy groups, disease foundations, and clinical and research institutions that are committed to the advancement of the field of regenerative medicine, and served ex officio from 2013 to 2014. He served as a Member of the Biotechnology Industry Organization (BIO) Emerging Companies Section Board from 2001 to 2004. Dr. Van Bokkelen served as a Member of the Kent State University Board of Trustees from 2001 to 2004. He is the recipient of numerous awards, including the Ernst & Young Entrepreneur of the Year award and SBN Visionary in Business Award. Dr. Van Bokkelen is also the Chairman of the Board of Governors for the National Center for Regenerative Medicine. He is a co-developer of the Synthetic Human Chromosome technology and has been awarded several patents. Dr. Van Bokkelen holds a Ph.D. in Genetics from Stanford University, a BA in Economics from the University of California at Berkeley and a B.A. in Molecular Biology from the University of California at Berkeley.

CEO Compensation
  • Gil's compensation has been consistent with company performance over the past year.
  • Gil's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Athersys management team in years:

3.1
Average Tenure
54
Average Age
  • The tenure for the Athersys management team is about average.
Management Team

Gil Van Bokkelen

TITLE
Co-Founder
COMPENSATION
$1M
AGE
57
TENURE
23.5 yrs

BJ Lehmann

TITLE
President
COMPENSATION
$1M
AGE
52
TENURE
12.8 yrs

John Harrington

TITLE
Co-Founder
COMPENSATION
$1M
AGE
51
TENURE
23.5 yrs

Laura Campbell

TITLE
Senior Vice President of Finance
COMPENSATION
$636K
AGE
54
TENURE
3.1 yrs

Manal Morsy

TITLE
Senior VP & Head of Global Regulatory Affairs
TENURE
6.3 yrs

Willie Mays

TITLE
VP of Regenerative Medicine & Head of Neuroscience Programs
TENURE
2.8 yrs

Anthony Ting

TITLE
VP of Regenerative Medicine & Head of Cardiopulmonary Programs
TENURE
2.8 yrs

Rakesh Ramachandran

TITLE
Head of Information Technology & Communications and VP
TENURE
2.3 yrs

Greg Liposky

TITLE
Senior VP of Commercial Manufacturing
AGE
63
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Athersys board of directors in years:

15.1
Average Tenure
68
Average Age
  • The average tenure for the Athersys board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

John Harrington

TITLE
Co-Founder
COMPENSATION
$1M
AGE
51
TENURE
23.5 yrs

Jeff Randall

TITLE
Independent Director
COMPENSATION
$105K
AGE
74
TENURE
11.6 yrs

Gil Van Bokkelen

TITLE
Co-Founder
COMPENSATION
$1M
AGE
57
TENURE
18.7 yrs

Lee Babiss

TITLE
Lead Independent Director
COMPENSATION
$108K
AGE
62
TENURE
5.5 yrs

Jim Shook

TITLE
Scientific and Clinical Advisor
AGE
78

C. Caskey

TITLE
Scientific and Clinical Advisor
AGE
78

Catherine Verfaillie

TITLE
Scientific and Clinical Advisor

Michael Simons

TITLE
Scientific and Clinical Advisor

Ira Mellman

TITLE
Scientific and Clinical Advisor

Gilbert Clincke

TITLE
Scientific and Clinical Advisor
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Athersys's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Athersys has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4LS News

Simply Wall St News

4LS Company Info

Description

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases. It also has license and collaboration agreements with RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Details
Name: Athersys, Inc.
4LS
Exchange: DB
Founded: 1995
$187,390,718
146,842,739
Website: http://www.athersys.com
Address: Athersys, Inc.
3201 Carnegie Avenue,
Cleveland,
Ohio, 44115,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ATHX Common Stock Nasdaq Capital Market US USD 11. Jun 2007
DB 4LS Common Stock Deutsche Boerse AG DE EUR 11. Jun 2007
Number of employees
Current staff
Staff numbers
75
Athersys employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 21:17
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/03/15
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.